Home Regeneron

Regeneron

Looking to expand your partner network with leading companies like Regeneron? Consider joining Inpart's global network for free.

Stay informed about the latest news about Regeneron by subscribing to our newsletter.

What is Regeneron best known for?

Regeneron is known for its innovative antibody therapies and biopharmaceutical research. The company has developed breakthrough treatments for conditions such as age-related macular degeneration, certain cancers, and inflammatory diseases. Regeneron gained widespread attention for its antibody cocktail used in the treatment of COVID-19.

Where is Regeneron located?

Regeneron is located in Tarrytown, New York, United States.

Got a news story for us related to Regeneron? Send it to us here.

Latest Posts

In Depth 26 Feb 2024

New non-opioid pain medication: how is the biotech industry fighting pain after the opioid crisis?

Find out how biotechs are fighting pain with new non-opioid pain medication, as they look to overcome the ongoing opioid crisis.

February 26, 2024 - 10 minutesmins - By Willow Shah-Neville

News and Trends 27 Jan 2023

Dupixent gets EU nod for children with severe atopic dermatitis

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for Dupixent (dupilumab), recommending expanded approval in the European Union (EU) to treat severe atopic dermatitis in children six months to five years old who are candidates for systemic therapy. The European Commission is expected to announce a final […]

January 27, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 22 Dec 2022

Positive Dupixent eosinophilic esophagitis phase 3 results

The New England Journal of Medicine has published results from a positive phase 3 trial showing adults and adolescents treated with Dupixent (dupilumab) 300 mg weekly experienced significant improvements in signs and symptoms of eosinophilic esophagitis (EoE), which were sustained for up to one year. EoE is a chronic, progressive inflammatory disease that damages the […]

December 22, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 15 Dec 2022

European Commission approves Dupixent as first and only targeted prurigo nodularis medicine

The European Commission (EC) has expanded the marketing authorization for Dupixent (dupilumab) in the European Union to treat adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy. Dupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement. To date, dupilumab has been studied across more than 60 clinical trials […]

December 15, 2022 - 5 minutesmins - By Jim Cornall

News and Trends 1 Dec 2022

Trial for HPV16 positive oropharyngeal cancer completes enrolment for phase 2

Netherlands-based ISA Pharmaceuticals B.V., has announced that it has completed enrolment in its phase 2 clinical trial. Named OpcemISA. The trial aims to checkpoint inhibitor therapy in patients with metastatic/advanced 1st and 2nd line HPV16 positive oropharyngeal cancer (OPC). The clinical stage biotech company is developing immunotherapies to treat cancers and infectious diseases, and has […]

December 1, 2022 - 2 minutesmins - By Liza Laws

News and Trends 11 Nov 2022

Prurigo nodularis treatment recommended for EU approval

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the approval of Dupixent (dupilumab) in the European Union (EU) to treat adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy. Dupilumab is being jointly developed by Sanofi and Regeneron. The European Commission is expected […]

November 11, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 11 Oct 2022

Late-breaking data shows significant remission in children with EoE

Late-breaking positive results from a phase 3 trial have shown that children with eosinophilic esophagitis (EoE) given a higher dose of Dupixent showed histological disease remission and signs of weight gain. At week 16, 68% of children aged one to 11 years with active EoE on the higher dose displayed the positive results during the […]

October 11, 2022 - 3 minutesmins - By Liza Laws

News and Trends 29 Sep 2022

Treatment for adults with chronic skin condition approved by FDA

The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis. Dupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement. To date, dupilumab has been studied across more than 60 clinical trials involving more than 10,000 patients with various chronic diseases […]

September 29, 2022 - 4 minutesmins - By Liza Laws

News and Trends 16 Sep 2022

Regeneron and Sanofi announce published trial results in children with dermatitis

Positive results from a phase 3 trial in children aged 6 months to five years old with uncontrolled moderate-to-severe dermatitis have been published. Regeneron Pharmaceuticals, Inc. and Sanofi made the announcement today (September 16) that the Lancet published details on the success of Dupixent (dupilumab). These data were the basis for the U.S. Food and […]

September 16, 2022 - 3 minutesmins - By Liza Laws

Horizone Therapeutics, Eye disease, eye, eyes

News and Trends 9 Sep 2022

Improved vision with less eye injections for patients after primary endpoints met in trials

The primary endpoints in two clinical trials investigating drug aflibercept 8 mg with 12 and 16-week dosing regimes, for patients with diabetic macular edema (DME) and wet age-related macular degeneration (wAMD), have been met. The trials, called PHOTON in DME and PULSAR in wAMD, both showed the dosing regimens achieved non-inferiority in vision gains compared […]

September 9, 2022 - 3 minutesmins - By Liza Laws

News and Trends 7 Sep 2022

OncoResponse and Regeneron to evaluate drug combo for patients with advanced cancer

OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of elite cancer responders, has announced a clinical supply agreement with Regeneron for PD-1 inhibitor Libtayo (cemiplimab). The supply agreement with Regeneron will support the evaluation of Libtayo in combination with OR2805, a fully human monoclonal antibody identified from an elite cancer responder […]

September 7, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 30 Jun 2020

Kymab Wins UK Supreme Court Antibody Battle Against Regeneron

The UK Supreme Court has supported an appeal by British biotech Kymab to revoke antibody drug patents held by US giant Regeneron, a decision that could make it harder for big patent holders to clamp down on small innovators in the biotech industry. Kymab and Regeneron have been battling it out in the UK since […]

June 30, 2020 - 4 minutesmins - By Anita Chakraverty

Resources

Categories

Promising cure for COPD: Is a breakthrough treatment within reach?

12 biotech unicorns revolutionizing the future of healthcare

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

RNA editing in humans: the race begins with first successful trial

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Promising cure for COPD: Is a breakthrough treatment within reach?

12 biotech unicorns revolutionizing the future of healthcare

Grab your free report on 3D organoids and explore their future potential

RNA editing in humans: the race begins with first successful trial

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Regeneron

What is Regeneron best known for?

Where is Regeneron located?

New non-opioid pain medication: how is the biotech industry fighting pain after the opioid crisis?

Dupixent gets EU nod for children with severe atopic dermatitis

Positive Dupixent eosinophilic esophagitis phase 3 results

European Commission approves Dupixent as first and only targeted prurigo nodularis medicine

Trial for HPV16 positive oropharyngeal cancer completes enrolment for phase 2

Prurigo nodularis treatment recommended for EU approval

Late-breaking data shows significant remission in children with EoE

Treatment for adults with chronic skin condition approved by FDA

Regeneron and Sanofi announce published trial results in children with dermatitis

Improved vision with less eye injections for patients after primary endpoints met in trials

OncoResponse and Regeneron to evaluate drug combo for patients with advanced cancer

Kymab Wins UK Supreme Court Antibody Battle Against Regeneron

Subscribe to our newsletter to get the latest biotech news!

Promising cure for COPD: Is a breakthrough treatment within reach?

12 biotech unicorns revolutionizing the future of healthcare

Grab your free report on 3D organoids and explore their future potential

RNA editing in humans: the race begins with first successful trial

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Promising cure for COPD: Is a breakthrough treatment within reach?

12 biotech unicorns revolutionizing the future of healthcare

Grab your free report on 3D organoids and explore their future potential

RNA editing in humans: the race begins with first successful trial

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!